STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuels

STAT PlusPharmalot Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuels Researcher Julien Pouille says cutting emissions is good for the climate, and good for ‘resilience’ Manage alerts for this article Email this article Share this article By Ed SilvermanJuly 30, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

The war with Iran has driven oil prices up, prompting concern that the supply of some medicines will be disrupted. But there is another consideration. In a new report, Unitaid emphasized that essential medicines are exposed to oil price volatility.

Specifically, the global health agency examined the effect rising oil prices could have on one HIV medication and found that manufacturing costs could rise by 15% if oil reaches $120 barrel, and 85% of those higher costs are driven by petrochemical ingredients. To push back, Julien Pouille, who leads the climate and health strategic team and is lead author of the report, argues that lessening reliance on petrochemical products would help mitigate rising medicine costs and improve the climate. This is an edited version of our conversation.

So what prompted this exploration?Advertisement As part of our access strategy, we have a climate and health strategy that looks into ways in which basically we can just advance product knowledge that’s good for health, but also good for climate.… And of course, in the context of the Middle East crisis… we thought it was very timely to look into, specifically, the relationship between medicine prices and oil prices, because we were anticipating that that could potentially lead to some risks in terms of access for people and the population we work for. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In drug pricing, HIV/AIDS, Pharmaceuticals, Policy, public health, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot July 30, 2026 STAT Plus: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more Pharmalot July 29, 2026 STAT Plus: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more Advertisement Pharmalot July 28, 2026 STAT Plus: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more Pharmalot July 27, 2026 STAT Plus: HIV resurgence is feared as global funding to combat the disease falls 18% Pharmalot July 27, 2026 STAT Plus: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more Subscriber Picks